{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T13:50:21Z","timestamp":1779371421262,"version":"3.53.1"},"update-to":[{"DOI":"10.1002\/14651858.cd009226.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000}}],"reference-count":82,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009226.pub3","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T17:23:07Z","timestamp":1655400187000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Rituximab for thyroid-associated ophthalmopathy"],"prefix":"10.1002","volume":"2022","author":[{"given":"Swan","family":"Kang","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital NHS Foundation Trust; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Hamed Azzam","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital NHS Foundation Trust; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Minakaran","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology; Moorfields Eye Hospital NHS Foundation Trust; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G","family":"Ezra","sequence":"additional","affiliation":[{"name":"Moorfields and UCL Institute of Ophthalmology BMRC; Moorfields Eye Hospital NHS Foundation Trust; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD009226.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD009226.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves' orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD009226.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1210\/jc.2006-2388","article-title":"B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study","volume":"92","author":"El Fassi","year":"2007","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"7","key":"10.1002\/14651858.CD009226.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1089\/thy.2006.16.709","article-title":"Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion","volume":"16","author":"El Fassi","year":"2006","journal-title":"Thyroid"},{"issue":"5","key":"10.1002\/14651858.CD009226.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/gut.2007.138305","article-title":"Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease","volume":"57","author":"El Fassi","year":"2008","journal-title":"Gut"},{"issue":"5","key":"10.1002\/14651858.CD009226.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1530\/EJE-08-0084","article-title":"Rituximab in relapsing Graves' disease, a phase II study","volume":"159","author":"Heemstra","year":"2008","journal-title":"European Journal of Endocrinology"},{"issue":"1","key":"10.1002\/14651858.CD009226.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ophtha.2009.05.029","article-title":"Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy","volume":"117","author":"Khanna","year":"2010","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD009226.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2265.2009.03762.x","article-title":"Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids","volume":"72","author":"Krassas","year":"2010","journal-title":"Clinical Endocrinology"},{"issue":"3","key":"10.1002\/14651858.CD009226.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/cen.12141","article-title":"The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid refractory Graves\u2019 orbitopathy","volume":"79","author":"Mitchell","journal-title":"Cinical Endocrinology"},{"issue":"1","key":"10.1002\/14651858.CD009226.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12016-007-8024-3","article-title":"Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy","volume":"34","author":"Bonara","year":"2008","journal-title":"Clinical Reviews in Allergy and Immunology"},{"issue":"1","key":"10.1002\/14651858.CD009226.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/eje.1.02325","article-title":"Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study","volume":"156","author":"Salvi","year":"2007","journal-title":"European Journal of Endocrinology"},{"issue":"2","key":"10.1002\/14651858.CD009226.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.clim.2008.12.005","article-title":"Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates","volume":"131","author":"Salvi","year":"2009","journal-title":"Clinical Immunology"},{"issue":"4","key":"10.1002\/14651858.CD009226.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1530\/eje.1.02119","article-title":"Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression","volume":"154","author":"Salvi","year":"2006","journal-title":"European Journal of Endocrinology"},{"issue":"1","key":"10.1002\/14651858.CD009226.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1001\/archopthalmol.2011.1215","article-title":"Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action","volume":"130","author":"Salvi","year":"2012","journal-title":"Archives of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD009226.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/IOP.0b013e3181c4dfde","article-title":"Rituximab for thyroid eye disease","volume":"26","author":"Silkiss","year":"2010","journal-title":"Ophthalmic Plastic and Reconstructive Surgery"},{"key":"10.1002\/14651858.CD009226.pub3-BIB0016|cit16","unstructured":"A prospective clinical study of monoclonal antibody treatment for refractory thyroid-associated ophthalmopathy trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2000036239"},{"key":"10.1002\/14651858.CD009226.pub3-BIB0017|cit17","unstructured":"Rituximab (RTX) therapy in steroid resistant patients or patients relapsing after intravenous steroids with active TAO Rescue RTX clinicaltrialsregister.eu\/ctr-search\/search?query=EUCTR2011-000899-33-SE+\u00a0"},{"issue":"11","key":"10.1002\/14651858.CD009226.pub3-BIB0018|cit18","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012984.pub2","article-title":"Tocilizumab for thyroid eye disease","author":"Azzam","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD009226.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves' ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD009226.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1210\/jcem-56-6-1139","article-title":"Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone","volume":"56","author":"Bartalena","year":"1983","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD009226.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1089\/thy.2007.0315","article-title":"Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy","volume":"18","author":"Bartalena","year":"2008","journal-title":"Thyroid"},{"issue":"12","key":"10.1002\/14651858.CD009226.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD009226.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 European Thyroid Association\/European Group on graves\u2019 orbitopathy guidelines for the management of graves\u2019 orbitopathy","volume":"5","author":"Bartalena","year":"2016","journal-title":"European Thyroid Journal"},{"issue":"12","key":"10.1002\/14651858.CD009226.pub3-BIB0024|cit24","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007630.pub2","article-title":"Surgical orbital decompression for thyroid eye disease","author":"Boboridis","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD009226.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jbspin.2008.08.002","article-title":"Regulatory T cells (Treg) in rheumatoid arthritis","volume":"76","author":"Boissier","year":"2009","journal-title":"Joint Bone Spine"},{"issue":"4","key":"10.1002\/14651858.CD009226.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdg175","article-title":"An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab","volume":"14","author":"Boye","year":"2003","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD009226.pub3-BIB0027|cit27","first-page":"747","article-title":"Graves' ophthalmopathy: current concepts regarding pathogenesis and management","volume":"14","author":"Burch","year":"1993","journal-title":"Endocrine Reviews"},{"issue":"9","key":"10.1002\/14651858.CD009226.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00417-020-04651-6","article-title":"Efficacy of rituximab in patients with Graves' orbitopathy: a retrospective multicenter nationwide study","volume":"258","author":"d\u2019Assigny Flamen","year":"2020","journal-title":"Graefes Archives for Clinical and Experimental Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD009226.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD009226.pub3-BIB0030|cit30","first-page":"844","article-title":"Slow-dose rituximab for active moderate to severe graves' orbitopathy resistant to conventional treatment","volume":"27","author":"\u00a0Andrei","year":"2019","journal-title":"Ocular\u00a0Immunology\u00a0and Inflammation"},{"issue":"6","key":"10.1002\/14651858.CD009226.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1055\/s-0029-1220935","article-title":"Current insights into the pathogenesis of Graves' orbitopathy","volume":"41","author":"Eckstein","year":"2009","journal-title":"Hormone and Metabolic Research"},{"issue":"7","key":"10.1002\/14651858.CD009226.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1089\/thy.2006.16.709","article-title":"Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion","volume":"16","author":"El Fassi","year":"2006","journal-title":"Thyroid"},{"issue":"6","key":"10.1002\/14651858.CD009226.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/00004728-197903060-00019","article-title":"Appearance of Graves' disease on orbital computed tomography","volume":"3","author":"Enzmann","year":"1979","journal-title":"Journal of Computer Assisted Tomography"},{"issue":"3","key":"10.1002\/14651858.CD009226.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1530\/eje.1.02230","article-title":"Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers","volume":"155","author":"Wiersinga","year":"2006","journal-title":"European Journal of Endocrinology"},{"issue":"7","key":"10.1002\/14651858.CD009226.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1136\/jclinpath-2012-200719","article-title":"Transcriptome-level microarray expression profiling implicates IGF-1 and Wnt signalling dysregulation in the pathogenesis of thyroid-associated orbitopathy","volume":"65","author":"Ezra","year":"2012","journal-title":"Journal of Clinical Pathology"},{"issue":"2","key":"10.1002\/14651858.CD009226.pub3-BIB0036|cit36","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"key":"10.1002\/14651858.CD009226.pub3-BIB0037|cit37","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT"},{"issue":"1","key":"10.1002\/14651858.CD009226.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1210\/en.2005-1018","article-title":"T helper type 1 and type 2 cytokines exert divergent influence on the induction of prostaglandin E2 and hyaluronan synthesis by interleukin-1beta in orbital fibroblasts: implications for the pathogenesis of thyroid-associated ophthalmopathy","volume":"147","author":"Han","year":"2006","journal-title":"Endocrinology"},{"issue":"1","key":"10.1002\/14651858.CD009226.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0165-2478(03)00032-4","article-title":"B-cell depletion with rituximab - a targeted therapy in Graves' disease and autoimmune thyroiditis","volume":"88","author":"Hasselbach","year":"2003","journal-title":"Immunology Letters"},{"key":"10.1002\/14651858.CD009226.pub3-BIB0040|cit40","unstructured":"Higgins JP Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017\u00a0 Available from www.training.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD009226.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/cen.13970","article-title":"Early low-dose rituximab for active thyroid eye disease: An effective and well-tolerated treatment","volume":"91","author":"\u00a0David","year":"2019","journal-title":"Clinical Endocrinology"},{"issue":"4","key":"10.1002\/14651858.CD009226.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2265.2005.02352.x","article-title":"Psychosocial morbidity of Graves' orbitopathy","volume":"63","author":"Kahaly","year":"2005","journal-title":"Clinical Endocrinology"},{"issue":"3","key":"10.1002\/14651858.CD009226.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/ard.2007.074229","article-title":"Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results","volume":"67","author":"Kavanaugh","year":"2008","journal-title":"Annual of Rheumatological Disease"},{"issue":"11","key":"10.1002\/14651858.CD009226.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2165\/11201110-000000000-00000","article-title":"Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma","volume":"70","author":"Keating","year":"2010","journal-title":"Drugs"},{"issue":"1","key":"10.1002\/14651858.CD009226.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.clim.2009.07.001","article-title":"Depletion of B lymphocytes in rheumatoid arthritis patients modifies IL-8-anti-IL-8 autoantibody network","volume":"113","author":"Keren","year":"2009","journal-title":"Clinical Immunology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD009226.pub3-BIB0046|cit46","first-page":"204","article-title":"Corticosteroids in the medical treatment of thyroid ophthalmopathy: when and how? Somatostatin analogues: where we stand today","volume":"7","author":"Krassas","year":"2010","journal-title":"Paediatric Endocrinology Reviews"},{"issue":"6011","key":"10.1002\/14651858.CD009226.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/314537a0","article-title":"Antigen-specific interaction between T and B cells","volume":"314","author":"Lanzavecchia","year":"1985","journal-title":"Nature"},{"issue":"2","key":"10.1002\/14651858.CD009226.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/IOP.0000000000001446","article-title":"Quality of life in thyroid eye disease: a systematic review","volume":"36","author":"Lee","year":"2020\u00a0","journal-title":"Ophthalmic Plastic and Reconstructive Surgery"},{"issue":"3","key":"10.1002\/14651858.CD009226.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clim.2008.01.011","article-title":"Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells","volume":"127","author":"Liossis","year":"2008","journal-title":"Clinical Immunology"},{"issue":"20","key":"10.1002\/14651858.CD009226.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","article-title":"Selenium and the course of mild Graves' orbitopathy","volume":"364","author":"Marcocci","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD009226.pub3-BIB0051|cit51","first-page":"3562","article-title":"Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blinded randomized study","volume":"86","author":"Marroci","year":"2001","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD009226.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","article-title":"Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy","volume":"47","author":"Mourits","year":"1997","journal-title":"Clinical Endocrinology"},{"issue":"5","key":"10.1002\/14651858.CD009226.pub3-BIB0053|cit53","first-page":"322","article-title":"Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves' ophthalmopathy: a preliminary study","volume":"11","author":"Ng","year":"2005","journal-title":"Hong Kong Medical Journal"},{"issue":"3","key":"10.1002\/14651858.CD009226.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/01658107.2015.1039140","article-title":"Rituximab in the treatment of thyroid eye disease: a review","volume":"39","author":"Ostrowski","journal-title":"Neuroophthalmology"},{"key":"10.1002\/14651858.CD009226.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: a randomized clinical trial","volume":"195","author":"Perez-Moreiras","year":"2018","journal-title":"American Journal of Ophthalmology"},{"issue":"22","key":"10.1002\/14651858.CD009226.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","article-title":"Rituximab, B-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD009226.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1210\/er.2002-0020","article-title":"Current perspective on the pathogenesis of Graves' disease and ophthalmopathy","volume":"24","author":"Prabhakar","year":"2003","journal-title":"Endocrine Reviews"},{"issue":"7","key":"10.1002\/14651858.CD009226.pub3-BIB0058|cit58","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007114.pub2","article-title":"Orbital radiotherapy for adult thyroid eye disease","author":"Rajendram","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD009226.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD009226.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00296-008-0719-0","article-title":"NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis","volume":"29","author":"Reis","year":"2009","journal-title":"Rheumatology International"},{"key":"10.1002\/14651858.CD009226.pub3-BIB0061|cit61","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2020"},{"issue":"4","key":"10.1002\/14651858.CD009226.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1530\/eje.1.02119","article-title":"Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression","volume":"154","author":"Salvi","year":"2006","journal-title":"European Journal of Endocrinology"},{"issue":"2","key":"10.1002\/14651858.CD009226.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.clim.2008.12.005","article-title":"Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates","volume":"131","author":"Salvi","year":"2009","journal-title":"Clinical Immunology"},{"issue":"3","key":"10.1002\/14651858.CD009226.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.survophthal.2012.10.006","article-title":"B-cell targeted therapy with rituximab for thyroid eye disease: closer to the clinic","volume":"58","author":"Shen","year":"2013","journal-title":"Survey of Ophthalmology"},{"issue":"18","key":"10.1002\/14651858.CD009226.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD009226.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/ard.2006.061002","article-title":"Consensus Statement on the use of rituximab in patients with rheumatoid arthritis","volume":"66","author":"Smolen","year":"2007","journal-title":"Annals of Rheumatic Diseases"},{"issue":"9","key":"10.1002\/14651858.CD009226.pub3-BIB0067|cit67","first-page":"3428","article-title":"Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture","volume":"81","author":"Sorisky","year":"1996","journal-title":"Journal of Clinical Endrocrinology and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD009226.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1530\/EJE-16-0552","article-title":"Rituximab therapy for Graves' orbitopathy - lessons from randomized control trials","volume":"176","author":"Stan","year":"2017","journal-title":"European Journal of Endocrinology"},{"issue":"8","key":"10.1002\/14651858.CD009226.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1210\/jc.2009-0376","article-title":"Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis","volume":"94","author":"Stiebel-Kalish","year":"2009","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD009226.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1210\/jc.2012-3873","article-title":"Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center","volume":"98","author":"Tanda","year":"2013","journal-title":"Journal of Clinical Endocrinology and Metabolism\u00a0"},{"issue":"3","key":"10.1002\/14651858.CD009226.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2265.2001.01241.x","article-title":"Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments","volume":"54","author":"Terwee","year":"2001","journal-title":"Clinical Endocrinology"},{"issue":"5","key":"10.1002\/14651858.CD009226.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1089\/thy.2020.0269","article-title":"Efficacy profile and safety implications of very low dose rituximab in patients with graves' orbitopathy","volume":"31","author":"Vannucchi","year":"2021","journal-title":"Thyroid\u00a0"},{"issue":"7","key":"10.1002\/14651858.CD009226.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nature Reviews Immunology"},{"issue":"9","key":"10.1002\/14651858.CD009226.pub3-BIB0074|cit74","first-page":"2830","article-title":"Untreated Graves' disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance","volume":"80","author":"Villadolid","year":"1995","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"10","key":"10.1002\/14651858.CD009226.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1210\/en.2006-0852","article-title":"Targeting B cells in Graves' disease","volume":"147","author":"Wang","year":"2006","journal-title":"Endocrinology"},{"key":"10.1002\/14651858.CD009226.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12886-018-0679-4","article-title":"Does rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? A systematic review and meta-analysis","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD009226.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0895-4356(98)00081-X","article-title":"Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project","volume":"51","author":"Gandek","year":"1998","journal-title":"Journal of Clinical Epidemiology"},{"issue":"17","key":"10.1002\/14651858.CD009226.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1056\/NEJM200010263431707","article-title":"Graves' disease","volume":"343","author":"Weetman","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD009226.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1089\/105072502761016476","article-title":"Epidemiology and prevention of Graves' ophthalmopathy","volume":"12","author":"Wiersinga","year":"2002","journal-title":"Thyroid"},{"issue":"8","key":"10.1002\/14651858.CD009226.pub3-BIB0080|cit80","first-page":"1379","article-title":"Meta-analysis of the efficacy of Rituximab in thyroid associated ophthalmopathy","volume":"20","author":"Yu","year":"2020","journal-title":"International Eye Science"},{"issue":"3","key":"10.1002\/14651858.CD009226.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/WNO.0b013e31814a5ef8","article-title":"Efficacy of corticosteroids and external beam radiation in the management of moderate to severe thyroid eye disease","volume":"27","author":"Zoumalan","year":"2007","journal-title":"Journal of Neuro-Opthalmology"},{"issue":"5","key":"10.1002\/14651858.CD009226.pub3-BIB0082|cit82","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009226.pub2","article-title":"Rituximab for thyroid-associated ophthalmopathy (Review)","author":"Minakaran","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T08:38:30Z","timestamp":1700728710000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009226.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Eyes and Vision Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":82,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009226.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]}}}